Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
Accuray, Inc. (ARAY)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$0.12-16.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ARAY yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Repayment of 3.75% Convertible Senior Notes | The company repaid its 3.75% convertible notes in 2026. | Intact | Failure to maintain debt repayment status | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk turnaround and execution story, not a proven durable compounder. The long-term thesis is intact for now, but management’s transformation and financing priorities remain at the watch stage.
The evidence snapshot does not provide valuation or market-expectation data, so whether ARAY is cheap, fair, or expensive versus peers is unclear. The business is loss-making, and recent quarterly misses raise the risk that expectations may be revised lower.
Recent financial performance is in the top half of its industry, and the latest reported earnings were in line. Over the next few quarters, results depend on cost and margin improvements and stronger financial footing; the next print carries elevated miss risk, and a guidance cut is a key concern.
The multi-year view hinges on whether management executes its transformation plan, strengthens its financial position through TCW agreements, and expands strategic partnerships. Near term, weaker employment data could weigh on healthcare names, while continued strength from sector bellwethers could support the backdrop; the listing-rule notice also remains a risk.
For the next 1 to 3 years, ARAY remains an unproven, high-risk execution story with encouraging recent performance but meaningful financial and operational uncertainty. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| It is working to fix Nasdaq listing issues. |
| Under Pressure |
| Nasdaq delisting or failure to meet listing rules |
Stock price $0.16 vs $1.00 target Stock price $0.16; reverse split approved to address bid price rule; no evidence of compliance resolution. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue near $445 million in fiscal 2026 | Accuray aims for about $445 million in revenue in fiscal 2026. | Intact | Revenue falls below $440 million in FY26 | Revenue: $100.919M FY2026-Q4; GAAP. Published target: ~$445 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 27, 2026100,919,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.14 → $-0.14 · observed estimates
$0.42B → $0.42B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-07-25 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-07-26 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-07-27 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-07-28 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-07-29 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-07-30 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-07-31 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-01 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-02 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-03 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-04 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-05 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-06 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-07 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-08 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-09 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-10 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-11 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-12 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-13 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-14 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-15 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-16 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-17 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-18 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-19 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-20 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-21 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-22 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-23 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-24 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-25 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-26 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-27 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-28 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-29 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-30 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-08-31 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-01 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-02 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-03 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-04 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-05 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-06 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-07 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-08 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-09 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-10 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-11 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-12 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-13 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-14 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-15 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-16 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-17 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-18 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-19 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-20 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-21 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-22 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-23 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-24 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-25 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-26 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-27 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-28 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-29 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-09-30 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-01 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-02 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-03 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-04 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-05 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-06 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-07 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-08 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-09 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-10 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-11 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-12 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-13 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-14 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-15 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-16 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-17 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-18 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-19 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-20 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-21 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-22 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-23 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-24 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-25 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-26 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-27 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-28 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-29 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-30 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-10-31 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-11-01 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-11-02 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-11-03 | $-0.14 | $422,700,000 | 1 / 1 |
| 2026-11-04 | $-0.14 | $422,700,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.